AGTC Announces Pricing of Initial Public Offering

GAINESVILLE, Fla., March 26, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation today announced the pricing of its initial public offering of 4,166,667 shares of its common stock at a price to the public of $12.00 per share, before underwriting discounts. All of the common stock is being offered by AGTC. In addition, AGTC has granted the underwriters a 30-day option to purchase up to an additional 625,000 shares at the initial public offering price to cover over-allotments, if any. The shares are expected to begin trading on the NASDAQ Global Market on March 27, 2014 under the symbol "AGTC."

BMO Capital Markets and Wedbush PacGrow Life Sciences are acting as the book-running managers for the offering and Cantor Fitzgerald & Co. and Roth Capital Partners are acting as co-managers.

The Securities and Exchange Commission declared effective a registration statement relating to these securities on March 26, 2014. The offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from BMO Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, Telephone: (800) 414-3627, Email: [email protected]; or from Wedbush PacGrow Life Sciences, 2 Embarcadero Center, Suite 600, San Francisco, CA 94111, Attention: Equity Syndicate Department, Telephone: (415) 274-6819.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe inherited orphan diseases in ophthalmology. AGTC's lead product candidates, which are each in the preclinical stage, focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are rare diseases of the eye, caused by mutations in single genes, that significantly affect visual function and currently lack effective medical treatments.

CONTACT: Media Contact:
         David Carey
         Lazar Partners Ltd.
         T: (212) 867-1768
         [email protected]

         Corporate Contact:
         Larry Bullock
         Chief Financial Officer
         Applied Genetic Technologies Corporation
         T: (386) 462-2204
         [email protected]

You May Also Be Interested In

• Men’s Wearhouse owner Tailored Brands, bankrupt in 2020, files for IPO
• Nuveen Churchill closes $100M note offering, totaling $400M due 2030
• Cognizant shareholder derivative settlement gets preliminary approval